Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.
about
Murine models to evaluate novel and conventional therapeutic strategies for cancerTranslation research: from accurate diagnosis to appropriate treatmentEstablishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical TestingEsophageal Cancer: Insights From Mouse ModelsMouse model of lymph node metastasis via afferent lymphatic vessels for development of imaging modalitiesEstablishment of a Non-Invasive Semi-Quantitative Bioluminescent Imaging Method for Monitoring of an Orthotopic Esophageal Cancer Mouse ModelRoutes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in miceMouse models in liver cancer research: A review of current literatureMolecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancermiRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancersRecapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibitionComprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer through optical molecular imagingImagable 4T1 model for the study of late stage breast cancer.An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouseFabrication of gold nanoparticles for targeted therapy in pancreatic cancer.A novel orthotopic mouse model of human anaplastic thyroid carcinomaTherapeutic effects of matrine on primary and metastatic breast cancer.Current animal models of bladder cancer: Awareness of translatability (Review)In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer.Animal models and therapeutic molecular targets of cancer: utility and limitations.Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging.Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer modelValidating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhChemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal modelsA versatile technique for the in vivo imaging of human tumor xenografts using near-infrared fluorochrome-conjugated macromolecule probes.Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Intravital microscopy in the mouse dorsal chamber model for the study of solid tumors.Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.Oncolytic vaccinia virus therapy of salivary gland carcinomaEvaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle.Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinomaReal-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancerEstablishment of patient-derived cancer xenografts in immunodeficient NOG mice.Preclinical approaches to study the biology and treatment of brain metastases.Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.Adenoviral-based immunotherapy provides local disease control in an orthotopic murine model of esophageal cancer.Animal models for exploring the pharmacokinetics of breast cancer therapiesWhat do, can and should we learn from models to evaluate potential anticancer agents?
P2860
Q24673595-65589101-D9DC-43FF-9D0D-8A4545DA271FQ24806201-816B5ACB-4CAF-4DB9-9DCC-CE7C587C14ADQ26750379-002EBAB3-C3D2-4178-B5E7-D3DC8A937F2CQ26783904-3ED3B713-626C-467D-BCBE-4E1759C6B162Q27316237-1F9432B0-4005-49E1-8FAA-EA32A06BAAAEQ27321510-97158AA6-2A2C-485D-8570-5CCBAC0DB50EQ27335400-FCBE8E08-3576-456B-B237-A2D7F858C75AQ27490350-1783C271-D161-46F0-B263-955DE324CA82Q28076041-8EC72A15-A82F-48FE-B29C-F73A21668B18Q28078451-04D56B0A-D9E4-4D17-A207-96C576D72FF6Q28484418-A652540A-602F-4465-846D-DACD077D9E1CQ28538538-334DF562-FAC1-4D2C-AC44-2F5BECCB6C8AQ33358981-EE638DBC-3D18-4626-B4D1-28EC0F7484D7Q33615020-8A140CB9-07BB-424A-93D0-C03FC1B34DDCQ33684453-E575ABE2-E7DD-49F6-9D2A-B287702B04DFQ33707844-3156E00C-1CBD-47BF-833E-507B17046D71Q33742371-59B5AF67-1BAE-47AE-9465-9C596AFC13F3Q33962620-CD86B370-9A5B-4E68-9DBA-E34FC62BEEF8Q34111542-055D93E0-A042-4971-8D79-0FFB905AB805Q34386828-B589BE6F-773B-4706-A875-24F0ADD92D6DQ34462433-9EEA09D0-BD5C-4B58-9E7A-9DBBC47C8F45Q34755674-4ECC6C75-07CE-405F-8A33-D0DEA5E3E7F8Q35001420-A6FC483D-ECC1-496E-813E-07C0C9F5B21BQ35014332-88E200A1-5B7F-4DA7-9CB1-F486E5F39F01Q35072877-43F8DE35-9195-4B24-9D2A-C40046E8CD78Q35073239-D23BCC66-977C-4D93-AF37-62A97BD8911FQ35110920-4EBCB7DF-E3E7-47EF-8845-739B83BE76DFQ35170403-4BEEEE24-F152-4BE9-98D2-9BD696EE356FQ35298115-6DAB2AA6-C561-46AE-84CC-00B677687CAEQ35546878-6AF59106-0EEF-4FFF-BB93-4749386FC3CBQ35549696-8D4F5A7F-26D1-4EBA-8B3D-D050E70A8776Q35551143-8DF0E57E-72B8-484C-8DD7-4B9989285AA5Q35602635-DA64F3D2-6F1D-4C9C-8C3F-0E54120B9718Q35678603-7300FB91-DA33-4DB7-93E2-A07FF420BD83Q35798580-109E29BA-E496-4F2F-9B76-44A00168A12FQ35967411-57D64521-2669-4504-B863-6411E660E3AAQ35996689-AAD631EE-E055-4C5D-AF47-F3A7CCE74423Q36004154-E0A07D8D-A66D-4FBA-83B8-1B4BD45891F9Q36093956-A2135857-8DC8-4B7A-90F1-B04646825671Q36430731-100E9D76-F441-4125-A003-8F9AB1FC188F
P2860
Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Orthotopic models of cancer fo ...... advantages and disadvantages.
@ast
Orthotopic models of cancer fo ...... advantages and disadvantages.
@en
type
label
Orthotopic models of cancer fo ...... advantages and disadvantages.
@ast
Orthotopic models of cancer fo ...... advantages and disadvantages.
@en
prefLabel
Orthotopic models of cancer fo ...... advantages and disadvantages.
@ast
Orthotopic models of cancer fo ...... advantages and disadvantages.
@en
P1476
Orthotopic models of cancer fo ...... advantages and disadvantages.
@en
P2093
P304
P356
10.1016/J.EJCA.2003.11.021
P577
2004-04-01T00:00:00Z